Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 6/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19011026 | 0.89 | CA1 (0.47) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL7971562 | 0.83 | MAOA (0.45) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL28406349 | 0.82 | HPGD (0.46) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL11663668 | 0.80 | MAOA (0.42) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL1635475 | 0.79 | MAOA (0.59) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL4961160 | 0.78 | ALDH1A1 (0.48) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL17431154 | 0.78 | MAOA (0.48) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL24662703 | 0.78 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL13677597 | 0.77 | MAOA (0.46) | KDM4EALDH1A1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL24381629 | 0.76 | KDM4E (0.48) | KDM4EALDH1A1HPGDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186725-A1 | METHOD FOR THE HOMOGENEOUS CATALYTIC REDUCTIVE AMINATION OF CARBONYL COMPOUNDS | BASF SE (DE) | 2018-07-05 | — | — | US | disclosed |
| US-9975837-B2 | Method for synthesizing optically active carbonyl compounds | BASF SE (DE) | 2018-05-22 | — | — | US | disclosed |
| US-20180057437-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | BASF SE (DE) | 2018-03-01 | — | — | US | disclosed |
| US-8623621-B2 | Method for producing optically active 2-methyl-alkanols | BASF SE (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110045560-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-METHYL-ALKANOLS | BASF AKTIENGESELLSCHAFT (DE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186725-A1 | METHOD FOR THE HOMOGENEOUS CATALYTIC REDUCTIVE AMINATION OF CARBONYL COMPOUNDS | CAT, AOC1, CYCS | KDM4E 589/4885ALDH1A1 553/4885HPGD 744/4885 |
| US-20180057437-A1 | METHOD FOR SYNTHESIZING OPTICALLY ACTIVE CARBONYL COMPOUNDS | CBR3, CBR1, HRH4 | KDM4E 2773/4885ALDH1A1 653/4885HPGD 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.